nodes	percent_of_prediction	percent_of_DWPC	metapath
Trifluoperazine—ABCB1—melanoma	0.203	1	CbGaD
Trifluoperazine—CYP1A2—Carmustine—melanoma	0.0715	0.323	CbGbCtD
Trifluoperazine—CYP1A2—Vemurafenib—melanoma	0.0565	0.256	CbGbCtD
Trifluoperazine—CYP1A2—Dacarbazine—melanoma	0.0433	0.196	CbGbCtD
Trifluoperazine—ABCB1—Dactinomycin—melanoma	0.0329	0.149	CbGbCtD
Trifluoperazine—ABCB1—Docetaxel—melanoma	0.017	0.0767	CbGbCtD
Trifluoperazine—Edema cerebral—Carmustine—melanoma	0.00967	0.0683	CcSEcCtD
Trifluoperazine—Edema cerebral—Temozolomide—melanoma	0.00935	0.066	CcSEcCtD
Trifluoperazine—S100A4—neck—melanoma	0.00557	0.0561	CbGeAlD
Trifluoperazine—Brain oedema—Carmustine—melanoma	0.00524	0.037	CcSEcCtD
Trifluoperazine—Brain oedema—Temozolomide—melanoma	0.00506	0.0357	CcSEcCtD
Trifluoperazine—CALM2—ear—melanoma	0.00454	0.0457	CbGeAlD
Trifluoperazine—CALM1—ear—melanoma	0.00452	0.0454	CbGeAlD
Trifluoperazine—Pigmentation disorder—Temozolomide—melanoma	0.00433	0.0306	CcSEcCtD
Trifluoperazine—S100A4—eye—melanoma	0.00415	0.0417	CbGeAlD
Trifluoperazine—S100A4—skin of body—melanoma	0.00361	0.0363	CbGeAlD
Trifluoperazine—S100A4—mammalian vulva—melanoma	0.00329	0.0331	CbGeAlD
Trifluoperazine—EBPL—head—melanoma	0.00298	0.03	CbGeAlD
Trifluoperazine—HTR2A—hindlimb—melanoma	0.00285	0.0287	CbGeAlD
Trifluoperazine—CALY—head—melanoma	0.00273	0.0274	CbGeAlD
Trifluoperazine—HTR2A—appendage—melanoma	0.00244	0.0246	CbGeAlD
Trifluoperazine—CALM2—endothelium—melanoma	0.00243	0.0245	CbGeAlD
Trifluoperazine—CALM1—endothelium—melanoma	0.00242	0.0244	CbGeAlD
Trifluoperazine—CALM2—hair follicle—melanoma	0.00239	0.0241	CbGeAlD
Trifluoperazine—S100A4—head—melanoma	0.00235	0.0237	CbGeAlD
Trifluoperazine—Photosensitivity—Vemurafenib—melanoma	0.00234	0.0165	CcSEcCtD
Trifluoperazine—CALM2—blood vessel—melanoma	0.00224	0.0226	CbGeAlD
Trifluoperazine—CALM1—blood vessel—melanoma	0.00223	0.0225	CbGeAlD
Trifluoperazine—XDH—mammalian vulva—melanoma	0.00211	0.0212	CbGeAlD
Trifluoperazine—EBPL—lymph node—melanoma	0.00209	0.021	CbGeAlD
Trifluoperazine—Extrapyramidal disorder—Temozolomide—melanoma	0.00192	0.0136	CcSEcCtD
Trifluoperazine—CALY—lymph node—melanoma	0.00191	0.0192	CbGeAlD
Trifluoperazine—Cholestasis—Temozolomide—melanoma	0.0019	0.0134	CcSEcCtD
Trifluoperazine—Eosinophilia—Vemurafenib—melanoma	0.00176	0.0124	CcSEcCtD
Trifluoperazine—Systemic lupus erythematosus—Docetaxel—melanoma	0.00174	0.0123	CcSEcCtD
Trifluoperazine—Menstruation irregular—Docetaxel—melanoma	0.00174	0.0123	CcSEcCtD
Trifluoperazine—Liver injury—Temozolomide—melanoma	0.00172	0.0121	CcSEcCtD
Trifluoperazine—S100A4—lymph node—melanoma	0.00165	0.0166	CbGeAlD
Trifluoperazine—Amenorrhoea—Temozolomide—melanoma	0.00165	0.0116	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Vemurafenib—melanoma	0.00162	0.0114	CcSEcCtD
Trifluoperazine—CALM2—neck—melanoma	0.0016	0.0161	CbGeAlD
Trifluoperazine—CALM1—neck—melanoma	0.0016	0.0161	CbGeAlD
Trifluoperazine—Gait disturbance—Carmustine—melanoma	0.00153	0.0108	CcSEcCtD
Trifluoperazine—CALM3—eye—melanoma	0.00152	0.0153	CbGeAlD
Trifluoperazine—CALM3—retina—melanoma	0.00151	0.0152	CbGeAlD
Trifluoperazine—Aplastic anaemia—Dactinomycin—melanoma	0.0015	0.0106	CcSEcCtD
Trifluoperazine—Gait disturbance—Temozolomide—melanoma	0.00148	0.0105	CcSEcCtD
Trifluoperazine—HTR2A—endothelium—melanoma	0.00147	0.0148	CbGeAlD
Trifluoperazine—HTR6—head—melanoma	0.00142	0.0143	CbGeAlD
Trifluoperazine—Oedema peripheral—Vemurafenib—melanoma	0.0014	0.00988	CcSEcCtD
Trifluoperazine—TNNC1—lymph node—melanoma	0.00139	0.014	CbGeAlD
Trifluoperazine—HTR2A—blood vessel—melanoma	0.00136	0.0137	CbGeAlD
Trifluoperazine—Ileus—Docetaxel—melanoma	0.00136	0.00959	CcSEcCtD
Trifluoperazine—SIGMAR1—eye—melanoma	0.00136	0.0137	CbGeAlD
Trifluoperazine—Aplastic anaemia—Temozolomide—melanoma	0.00136	0.00959	CcSEcCtD
Trifluoperazine—Gynaecomastia—Carmustine—melanoma	0.00134	0.00945	CcSEcCtD
Trifluoperazine—Erythema—Vemurafenib—melanoma	0.00124	0.00873	CcSEcCtD
Trifluoperazine—CALM3—mammalian vulva—melanoma	0.00121	0.0121	CbGeAlD
Trifluoperazine—CALM2—eye—melanoma	0.00119	0.012	CbGeAlD
Trifluoperazine—CALM1—eye—melanoma	0.00119	0.012	CbGeAlD
Trifluoperazine—CALM2—retina—melanoma	0.00118	0.0119	CbGeAlD
Trifluoperazine—CALM1—retina—melanoma	0.00118	0.0118	CbGeAlD
Trifluoperazine—Nasal congestion—Temozolomide—melanoma	0.00115	0.00814	CcSEcCtD
Trifluoperazine—Dermatitis exfoliative—Temozolomide—melanoma	0.00111	0.00785	CcSEcCtD
Trifluoperazine—DRD2—eye—melanoma	0.0011	0.011	CbGeAlD
Trifluoperazine—Amenorrhoea—Docetaxel—melanoma	0.00109	0.00773	CcSEcCtD
Trifluoperazine—DRD2—retina—melanoma	0.00109	0.0109	CbGeAlD
Trifluoperazine—Cough—Vemurafenib—melanoma	0.00108	0.00762	CcSEcCtD
Trifluoperazine—SIGMAR1—mammalian vulva—melanoma	0.00108	0.0108	CbGeAlD
Trifluoperazine—Bronchospasm—Bleomycin—melanoma	0.00106	0.00747	CcSEcCtD
Trifluoperazine—CALM2—skin of body—melanoma	0.00104	0.0105	CbGeAlD
Trifluoperazine—CALM1—skin of body—melanoma	0.00103	0.0104	CbGeAlD
Trifluoperazine—Pancytopenia—Bleomycin—melanoma	0.00102	0.00721	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Vemurafenib—melanoma	0.00101	0.00713	CcSEcCtD
Trifluoperazine—Dysphagia—Dactinomycin—melanoma	0.001	0.00708	CcSEcCtD
Trifluoperazine—Skin disorder—Vemurafenib—melanoma	0.00098	0.00692	CcSEcCtD
Trifluoperazine—HTR2A—neck—melanoma	0.000973	0.00979	CbGeAlD
Trifluoperazine—Hepatocellular injury—Docetaxel—melanoma	0.000962	0.00679	CcSEcCtD
Trifluoperazine—Muscular weakness—Carmustine—melanoma	0.000958	0.00676	CcSEcCtD
Trifluoperazine—Pancytopenia—Dactinomycin—melanoma	0.000952	0.00673	CcSEcCtD
Trifluoperazine—CALM2—mammalian vulva—melanoma	0.000947	0.00953	CbGeAlD
Trifluoperazine—Hypotension—Vemurafenib—melanoma	0.000943	0.00666	CcSEcCtD
Trifluoperazine—CALM1—mammalian vulva—melanoma	0.000943	0.00949	CbGeAlD
Trifluoperazine—Dysphagia—Carmustine—melanoma	0.000939	0.00663	CcSEcCtD
Trifluoperazine—Muscular weakness—Temozolomide—melanoma	0.000926	0.00654	CcSEcCtD
Trifluoperazine—Dysphagia—Temozolomide—melanoma	0.000907	0.00641	CcSEcCtD
Trifluoperazine—Pancytopenia—Carmustine—melanoma	0.000891	0.00629	CcSEcCtD
Trifluoperazine—ABCB1—blood vessel—melanoma	0.000891	0.00897	CbGeAlD
Trifluoperazine—Decreased appetite—Vemurafenib—melanoma	0.000877	0.0062	CcSEcCtD
Trifluoperazine—Fatigue—Vemurafenib—melanoma	0.00087	0.00615	CcSEcCtD
Trifluoperazine—HRH1—eye—melanoma	0.000866	0.00872	CbGeAlD
Trifluoperazine—Constipation—Vemurafenib—melanoma	0.000863	0.0061	CcSEcCtD
Trifluoperazine—Pancytopenia—Temozolomide—melanoma	0.000861	0.00608	CcSEcCtD
Trifluoperazine—CHRM2—head—melanoma	0.00085	0.00855	CbGeAlD
Trifluoperazine—Hyperglycaemia—Carmustine—melanoma	0.000847	0.00598	CcSEcCtD
Trifluoperazine—Erectile dysfunction—Temozolomide—melanoma	0.000835	0.0059	CcSEcCtD
Trifluoperazine—Agranulocytosis—Dactinomycin—melanoma	0.000835	0.00589	CcSEcCtD
Trifluoperazine—Photosensitivity reaction—Temozolomide—melanoma	0.000828	0.00585	CcSEcCtD
Trifluoperazine—Weight increased—Temozolomide—melanoma	0.000826	0.00583	CcSEcCtD
Trifluoperazine—HTR2C—head—melanoma	0.000819	0.00824	CbGeAlD
Trifluoperazine—Hyperglycaemia—Temozolomide—melanoma	0.000818	0.00578	CcSEcCtD
Trifluoperazine—Body temperature increased—Vemurafenib—melanoma	0.000798	0.00563	CcSEcCtD
Trifluoperazine—Erythema—Bleomycin—melanoma	0.000749	0.00529	CcSEcCtD
Trifluoperazine—Hypersensitivity—Vemurafenib—melanoma	0.000744	0.00525	CcSEcCtD
Trifluoperazine—Oedema peripheral—Carmustine—melanoma	0.00074	0.00523	CcSEcCtD
Trifluoperazine—Asthenia—Vemurafenib—melanoma	0.000724	0.00511	CcSEcCtD
Trifluoperazine—HTR2A—eye—melanoma	0.000724	0.00728	CbGeAlD
Trifluoperazine—HTR2A—retina—melanoma	0.000717	0.00722	CbGeAlD
Trifluoperazine—Oedema peripheral—Temozolomide—melanoma	0.000715	0.00505	CcSEcCtD
Trifluoperazine—Pruritus—Vemurafenib—melanoma	0.000714	0.00504	CcSEcCtD
Trifluoperazine—Erythema—Dactinomycin—melanoma	0.000699	0.00493	CcSEcCtD
Trifluoperazine—HTR1A—head—melanoma	0.000689	0.00694	CbGeAlD
Trifluoperazine—HRH1—mammalian vulva—melanoma	0.000687	0.00692	CbGeAlD
Trifluoperazine—CALM2—head—melanoma	0.000677	0.00682	CbGeAlD
Trifluoperazine—CALM1—head—melanoma	0.000674	0.00679	CbGeAlD
Trifluoperazine—Leukopenia—Bleomycin—melanoma	0.000671	0.00474	CcSEcCtD
Trifluoperazine—Dizziness—Vemurafenib—melanoma	0.000667	0.00471	CcSEcCtD
Trifluoperazine—Erythema—Carmustine—melanoma	0.000654	0.00462	CcSEcCtD
Trifluoperazine—Cough—Bleomycin—melanoma	0.000654	0.00462	CcSEcCtD
Trifluoperazine—Rash—Vemurafenib—melanoma	0.000636	0.00449	CcSEcCtD
Trifluoperazine—Dermatitis—Vemurafenib—melanoma	0.000636	0.00449	CcSEcCtD
Trifluoperazine—ADRA1A—head—melanoma	0.000635	0.0064	CbGeAlD
Trifluoperazine—Headache—Vemurafenib—melanoma	0.000632	0.00447	CcSEcCtD
Trifluoperazine—Erythema—Temozolomide—melanoma	0.000632	0.00446	CcSEcCtD
Trifluoperazine—Leukopenia—Dactinomycin—melanoma	0.000626	0.00442	CcSEcCtD
Trifluoperazine—DRD2—head—melanoma	0.000623	0.00627	CbGeAlD
Trifluoperazine—Antrafenine—PTGS2—melanoma	0.00062	0.21	CrCbGaD
Trifluoperazine—Vision blurred—Carmustine—melanoma	0.000616	0.00435	CcSEcCtD
Trifluoperazine—Tremor—Carmustine—melanoma	0.000613	0.00433	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Bleomycin—melanoma	0.000612	0.00432	CcSEcCtD
Trifluoperazine—CALM3—lymph node—melanoma	0.000604	0.00608	CbGeAlD
Trifluoperazine—Dysphagia—Docetaxel—melanoma	0.000603	0.00426	CcSEcCtD
Trifluoperazine—Agitation—Carmustine—melanoma	0.000601	0.00424	CcSEcCtD
Trifluoperazine—Nausea—Vemurafenib—melanoma	0.0006	0.00423	CcSEcCtD
Trifluoperazine—Vision blurred—Temozolomide—melanoma	0.000596	0.00421	CcSEcCtD
Trifluoperazine—Bronchospasm—Docetaxel—melanoma	0.000593	0.00419	CcSEcCtD
Trifluoperazine—Tremor—Temozolomide—melanoma	0.000592	0.00418	CcSEcCtD
Trifluoperazine—Leukopenia—Carmustine—melanoma	0.000585	0.00413	CcSEcCtD
Trifluoperazine—Anorexia—Bleomycin—melanoma	0.000583	0.00412	CcSEcCtD
Trifluoperazine—Agitation—Temozolomide—melanoma	0.000581	0.0041	CcSEcCtD
Trifluoperazine—Angioedema—Temozolomide—melanoma	0.000578	0.00408	CcSEcCtD
Trifluoperazine—Pancytopenia—Docetaxel—melanoma	0.000573	0.00405	CcSEcCtD
Trifluoperazine—Hypotension—Bleomycin—melanoma	0.000571	0.00404	CcSEcCtD
Trifluoperazine—Convulsion—Carmustine—melanoma	0.000567	0.004	CcSEcCtD
Trifluoperazine—Leukopenia—Temozolomide—melanoma	0.000566	0.004	CcSEcCtD
Trifluoperazine—Cough—Temozolomide—melanoma	0.000552	0.00389	CcSEcCtD
Trifluoperazine—Weight increased—Docetaxel—melanoma	0.000549	0.00388	CcSEcCtD
Trifluoperazine—Convulsion—Temozolomide—melanoma	0.000548	0.00387	CcSEcCtD
Trifluoperazine—Dyspnoea—Bleomycin—melanoma	0.000545	0.00385	CcSEcCtD
Trifluoperazine—Anorexia—Dactinomycin—melanoma	0.000544	0.00384	CcSEcCtD
Trifluoperazine—SIGMAR1—lymph node—melanoma	0.00054	0.00543	CbGeAlD
Trifluoperazine—Decreased appetite—Bleomycin—melanoma	0.000532	0.00375	CcSEcCtD
Trifluoperazine—Dry mouth—Temozolomide—melanoma	0.000526	0.00372	CcSEcCtD
Trifluoperazine—Jaundice—Docetaxel—melanoma	0.000524	0.0037	CcSEcCtD
Trifluoperazine—Anaphylactic shock—Temozolomide—melanoma	0.000516	0.00364	CcSEcCtD
Trifluoperazine—Anorexia—Carmustine—melanoma	0.000509	0.00359	CcSEcCtD
Trifluoperazine—Agranulocytosis—Docetaxel—melanoma	0.000502	0.00354	CcSEcCtD
Trifluoperazine—Skin disorder—Temozolomide—melanoma	0.000501	0.00354	CcSEcCtD
Trifluoperazine—Hypotension—Carmustine—melanoma	0.000499	0.00352	CcSEcCtD
Trifluoperazine—Decreased appetite—Dactinomycin—melanoma	0.000496	0.0035	CcSEcCtD
Trifluoperazine—HRH1—head—melanoma	0.000492	0.00495	CbGeAlD
Trifluoperazine—Fatigue—Dactinomycin—melanoma	0.000492	0.00347	CcSEcCtD
Trifluoperazine—Anorexia—Temozolomide—melanoma	0.000492	0.00347	CcSEcCtD
Trifluoperazine—Urticaria—Bleomycin—melanoma	0.000486	0.00343	CcSEcCtD
Trifluoperazine—Body temperature increased—Bleomycin—melanoma	0.000483	0.00341	CcSEcCtD
Trifluoperazine—Insomnia—Carmustine—melanoma	0.000483	0.00341	CcSEcCtD
Trifluoperazine—Dyspnoea—Carmustine—melanoma	0.000476	0.00336	CcSEcCtD
Trifluoperazine—Oedema peripheral—Docetaxel—melanoma	0.000476	0.00336	CcSEcCtD
Trifluoperazine—Somnolence—Carmustine—melanoma	0.000475	0.00335	CcSEcCtD
Trifluoperazine—CALM2—lymph node—melanoma	0.000474	0.00477	CbGeAlD
Trifluoperazine—CALM1—lymph node—melanoma	0.000472	0.00475	CbGeAlD
Trifluoperazine—ABCB1—retina—melanoma	0.00047	0.00473	CbGeAlD
Trifluoperazine—Insomnia—Temozolomide—melanoma	0.000467	0.00329	CcSEcCtD
Trifluoperazine—Decreased appetite—Carmustine—melanoma	0.000464	0.00328	CcSEcCtD
Trifluoperazine—Dyspnoea—Temozolomide—melanoma	0.00046	0.00325	CcSEcCtD
Trifluoperazine—Somnolence—Temozolomide—melanoma	0.000459	0.00324	CcSEcCtD
Trifluoperazine—Constipation—Carmustine—melanoma	0.000456	0.00322	CcSEcCtD
Trifluoperazine—Body temperature increased—Dactinomycin—melanoma	0.000451	0.00318	CcSEcCtD
Trifluoperazine—Hypersensitivity—Bleomycin—melanoma	0.000451	0.00318	CcSEcCtD
Trifluoperazine—Decreased appetite—Temozolomide—melanoma	0.000448	0.00317	CcSEcCtD
Trifluoperazine—Fatigue—Temozolomide—melanoma	0.000445	0.00314	CcSEcCtD
Trifluoperazine—Constipation—Temozolomide—melanoma	0.000441	0.00312	CcSEcCtD
Trifluoperazine—Asthenia—Bleomycin—melanoma	0.000439	0.0031	CcSEcCtD
Trifluoperazine—Pruritus—Bleomycin—melanoma	0.000433	0.00306	CcSEcCtD
Trifluoperazine—Body temperature increased—Carmustine—melanoma	0.000422	0.00298	CcSEcCtD
Trifluoperazine—Erythema—Docetaxel—melanoma	0.00042	0.00297	CcSEcCtD
Trifluoperazine—Hypersensitivity—Dactinomycin—melanoma	0.00042	0.00297	CcSEcCtD
Trifluoperazine—HTR2A—head—melanoma	0.000411	0.00413	CbGeAlD
Trifluoperazine—Urticaria—Temozolomide—melanoma	0.00041	0.00289	CcSEcCtD
Trifluoperazine—Asthenia—Dactinomycin—melanoma	0.000409	0.00289	CcSEcCtD
Trifluoperazine—Body temperature increased—Temozolomide—melanoma	0.000408	0.00288	CcSEcCtD
Trifluoperazine—Muscle spasms—Docetaxel—melanoma	0.000404	0.00285	CcSEcCtD
Trifluoperazine—Hypersensitivity—Carmustine—melanoma	0.000393	0.00278	CcSEcCtD
Trifluoperazine—Rash—Bleomycin—melanoma	0.000386	0.00272	CcSEcCtD
Trifluoperazine—Dermatitis—Bleomycin—melanoma	0.000385	0.00272	CcSEcCtD
Trifluoperazine—Asthenia—Carmustine—melanoma	0.000383	0.0027	CcSEcCtD
Trifluoperazine—Hypersensitivity—Temozolomide—melanoma	0.00038	0.00268	CcSEcCtD
Trifluoperazine—ABCB1—mammalian vulva—melanoma	0.000376	0.00379	CbGeAlD
Trifluoperazine—Leukopenia—Docetaxel—melanoma	0.000376	0.00266	CcSEcCtD
Trifluoperazine—Asthenia—Temozolomide—melanoma	0.00037	0.00261	CcSEcCtD
Trifluoperazine—Cough—Docetaxel—melanoma	0.000367	0.00259	CcSEcCtD
Trifluoperazine—Pruritus—Temozolomide—melanoma	0.000365	0.00258	CcSEcCtD
Trifluoperazine—Convulsion—Docetaxel—melanoma	0.000364	0.00257	CcSEcCtD
Trifluoperazine—Nausea—Bleomycin—melanoma	0.000363	0.00257	CcSEcCtD
Trifluoperazine—Rash—Dactinomycin—melanoma	0.00036	0.00254	CcSEcCtD
Trifluoperazine—Dizziness—Carmustine—melanoma	0.000353	0.00249	CcSEcCtD
Trifluoperazine—Dry mouth—Docetaxel—melanoma	0.00035	0.00247	CcSEcCtD
Trifluoperazine—HRH1—lymph node—melanoma	0.000344	0.00347	CbGeAlD
Trifluoperazine—Anaphylactic shock—Docetaxel—melanoma	0.000343	0.00242	CcSEcCtD
Trifluoperazine—Dizziness—Temozolomide—melanoma	0.000341	0.00241	CcSEcCtD
Trifluoperazine—Nausea—Dactinomycin—melanoma	0.000339	0.00239	CcSEcCtD
Trifluoperazine—Rash—Carmustine—melanoma	0.000337	0.00238	CcSEcCtD
Trifluoperazine—Dermatitis—Carmustine—melanoma	0.000336	0.00237	CcSEcCtD
Trifluoperazine—Headache—Carmustine—melanoma	0.000334	0.00236	CcSEcCtD
Trifluoperazine—Skin disorder—Docetaxel—melanoma	0.000333	0.00235	CcSEcCtD
Trifluoperazine—Anorexia—Docetaxel—melanoma	0.000327	0.00231	CcSEcCtD
Trifluoperazine—Rash—Temozolomide—melanoma	0.000325	0.0023	CcSEcCtD
Trifluoperazine—Dermatitis—Temozolomide—melanoma	0.000325	0.00229	CcSEcCtD
Trifluoperazine—Headache—Temozolomide—melanoma	0.000323	0.00228	CcSEcCtD
Trifluoperazine—Hypotension—Docetaxel—melanoma	0.000321	0.00226	CcSEcCtD
Trifluoperazine—Nausea—Carmustine—melanoma	0.000317	0.00224	CcSEcCtD
Trifluoperazine—Insomnia—Docetaxel—melanoma	0.00031	0.00219	CcSEcCtD
Trifluoperazine—Nausea—Temozolomide—melanoma	0.000306	0.00216	CcSEcCtD
Trifluoperazine—Dyspnoea—Docetaxel—melanoma	0.000306	0.00216	CcSEcCtD
Trifluoperazine—Somnolence—Docetaxel—melanoma	0.000305	0.00215	CcSEcCtD
Trifluoperazine—Decreased appetite—Docetaxel—melanoma	0.000298	0.00211	CcSEcCtD
Trifluoperazine—Fatigue—Docetaxel—melanoma	0.000296	0.00209	CcSEcCtD
Trifluoperazine—Constipation—Docetaxel—melanoma	0.000293	0.00207	CcSEcCtD
Trifluoperazine—Flupentixol—ABCB1—melanoma	0.000279	0.0947	CrCbGaD
Trifluoperazine—Clozapine—CYP1B1—melanoma	0.000272	0.0922	CrCbGaD
Trifluoperazine—Body temperature increased—Docetaxel—melanoma	0.000271	0.00191	CcSEcCtD
Trifluoperazine—ABCB1—head—melanoma	0.000269	0.00271	CbGeAlD
Trifluoperazine—Hypersensitivity—Docetaxel—melanoma	0.000253	0.00178	CcSEcCtD
Trifluoperazine—Asthenia—Docetaxel—melanoma	0.000246	0.00174	CcSEcCtD
Trifluoperazine—Pruritus—Docetaxel—melanoma	0.000243	0.00171	CcSEcCtD
Trifluoperazine—Dizziness—Docetaxel—melanoma	0.000227	0.0016	CcSEcCtD
Trifluoperazine—Rash—Docetaxel—melanoma	0.000216	0.00153	CcSEcCtD
Trifluoperazine—Dermatitis—Docetaxel—melanoma	0.000216	0.00153	CcSEcCtD
Trifluoperazine—Headache—Docetaxel—melanoma	0.000215	0.00152	CcSEcCtD
Trifluoperazine—Nausea—Docetaxel—melanoma	0.000204	0.00144	CcSEcCtD
Trifluoperazine—ABCB1—lymph node—melanoma	0.000188	0.0019	CbGeAlD
Trifluoperazine—Nefazodone—ABCB1—melanoma	0.000156	0.0529	CrCbGaD
Trifluoperazine—Triflupromazine—ABCB1—melanoma	0.000152	0.0516	CrCbGaD
Trifluoperazine—Acepromazine—ALB—melanoma	0.000147	0.05	CrCbGaD
Trifluoperazine—Trazodone—ABCB1—melanoma	0.000144	0.049	CrCbGaD
Trifluoperazine—Thioproperazine—ALB—melanoma	0.000144	0.0489	CrCbGaD
Trifluoperazine—Pipotiazine—ALB—melanoma	0.000142	0.0481	CrCbGaD
Trifluoperazine—Thiothixene—ALB—melanoma	0.000142	0.0481	CrCbGaD
Trifluoperazine—Fluphenazine—ABCB1—melanoma	0.000117	0.0396	CrCbGaD
Trifluoperazine—Clomipramine—ALB—melanoma	0.000112	0.038	CrCbGaD
Trifluoperazine—Clomipramine—ABCB1—melanoma	0.000107	0.0363	CrCbGaD
Trifluoperazine—Promethazine—ABCB1—melanoma	9.48e-05	0.0321	CrCbGaD
Trifluoperazine—Quetiapine—ABCB1—melanoma	9.07e-05	0.0307	CrCbGaD
Trifluoperazine—Clozapine—ABCB1—melanoma	7.8e-05	0.0264	CrCbGaD
Trifluoperazine—Chlorpromazine—ALB—melanoma	7.69e-05	0.0261	CrCbGaD
Trifluoperazine—Chlorpromazine—ABCB1—melanoma	7.34e-05	0.0249	CrCbGaD
Trifluoperazine—ABCB1—Metabolism—ALB—melanoma	4.21e-06	1.27e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—KRAS—melanoma	4.21e-06	1.27e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—MYC—melanoma	4.21e-06	1.27e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MMP9—melanoma	4.21e-06	1.27e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—CDKN1A—melanoma	4.2e-06	1.27e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MAPK3—melanoma	4.2e-06	1.27e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—PTEN—melanoma	4.2e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—CDKN1A—melanoma	4.19e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—MAPK3—melanoma	4.19e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—MAPK3—melanoma	4.19e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—PTEN—melanoma	4.18e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—NFKB1—melanoma	4.17e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—IL6—melanoma	4.17e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling by GPCR—AKT1—melanoma	4.17e-06	1.26e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—NFKB1—melanoma	4.16e-06	1.25e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling by GPCR—AKT1—melanoma	4.16e-06	1.25e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—ERBB2—melanoma	4.16e-06	1.25e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—MAPK1—melanoma	4.12e-06	1.24e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—EGFR—melanoma	4.12e-06	1.24e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MYC—melanoma	4.11e-06	1.24e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PIK3CB—melanoma	4.1e-06	1.24e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PTEN—melanoma	4.1e-06	1.24e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PTEN—melanoma	4.1e-06	1.24e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—PIK3CA—melanoma	4.1e-06	1.23e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—PIK3CA—melanoma	4.1e-06	1.23e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling by GPCR—AKT1—melanoma	4.09e-06	1.23e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MYC—melanoma	4.09e-06	1.23e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling by GPCR—AKT1—melanoma	4.08e-06	1.23e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MDM2—melanoma	4.08e-06	1.23e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MDM2—melanoma	4.08e-06	1.23e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—KRAS—melanoma	4.07e-06	1.23e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—KRAS—melanoma	4.07e-06	1.23e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—MYC—melanoma	4.07e-06	1.23e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—MYC—melanoma	4.07e-06	1.23e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.07e-06	1.22e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—ERBB2—melanoma	4.02e-06	1.21e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—ERBB2—melanoma	4.02e-06	1.21e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—MAPK1—melanoma	4.02e-06	1.21e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—EGFR—melanoma	4.02e-06	1.21e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—MAPK1—melanoma	4e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—EGFR—melanoma	4e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—MAPK1—melanoma	3.98e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—MAPK1—melanoma	3.98e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—EGFR—melanoma	3.98e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—EGFR—melanoma	3.98e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PIK3CB—melanoma	3.97e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PIK3CB—melanoma	3.97e-06	1.2e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CXCL8—melanoma	3.94e-06	1.19e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—VEGFA—melanoma	3.92e-06	1.18e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—HRAS—melanoma	3.92e-06	1.18e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—KRAS—melanoma	3.89e-06	1.17e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—STAT3—melanoma	3.88e-06	1.17e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PIK3CG—melanoma	3.88e-06	1.17e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—NRAS—melanoma	3.87e-06	1.17e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—PIK3CA—melanoma	3.87e-06	1.17e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—VEGFA—melanoma	3.86e-06	1.16e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CDKN1B—melanoma	3.85e-06	1.16e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—VEGFA—melanoma	3.85e-06	1.16e-05	CbGpPWpGaD
Trifluoperazine—HTR6—Signaling Pathways—AKT1—melanoma	3.85e-06	1.16e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—STAT3—melanoma	3.82e-06	1.15e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CXCL8—melanoma	3.82e-06	1.15e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CXCL8—melanoma	3.82e-06	1.15e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—STAT3—melanoma	3.81e-06	1.15e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—NRAS—melanoma	3.81e-06	1.15e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—NRAS—melanoma	3.8e-06	1.15e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—KRAS—melanoma	3.8e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—HRAS—melanoma	3.79e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—HRAS—melanoma	3.79e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—VEGFA—melanoma	3.79e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—VEGFA—melanoma	3.78e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—KRAS—melanoma	3.78e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CASP3—melanoma	3.78e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IL2—melanoma	3.77e-06	1.14e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—KRAS—melanoma	3.76e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—KRAS—melanoma	3.76e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—STAT3—melanoma	3.75e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—IL6—melanoma	3.75e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—PIK3CA—melanoma	3.74e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—PIK3CA—melanoma	3.74e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—NRAS—melanoma	3.74e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—STAT3—melanoma	3.74e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PPARG—melanoma	3.74e-06	1.13e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—NRAS—melanoma	3.73e-06	1.12e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CDKN1B—melanoma	3.73e-06	1.12e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CDKN1B—melanoma	3.73e-06	1.12e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PIK3CB—melanoma	3.72e-06	1.12e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MAPK3—melanoma	3.71e-06	1.12e-05	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PTGS2—melanoma	3.69e-06	1.11e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CCND1—melanoma	3.67e-06	1.11e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CASP3—melanoma	3.65e-06	1.1e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CASP3—melanoma	3.65e-06	1.1e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MAPK3—melanoma	3.65e-06	1.1e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IL2—melanoma	3.65e-06	1.1e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IL2—melanoma	3.65e-06	1.1e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MAPK3—melanoma	3.64e-06	1.1e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CTNNB1—melanoma	3.64e-06	1.1e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—IL6—melanoma	3.63e-06	1.09e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—IL6—melanoma	3.63e-06	1.09e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MYC—melanoma	3.61e-06	1.09e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MAPK3—melanoma	3.58e-06	1.08e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—HRAS—melanoma	3.58e-06	1.08e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MAPK3—melanoma	3.57e-06	1.08e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—PIK3CA—melanoma	3.57e-06	1.08e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MMP9—melanoma	3.57e-06	1.07e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—CDKN1A—melanoma	3.55e-06	1.07e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CCND1—melanoma	3.55e-06	1.07e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CCND1—melanoma	3.55e-06	1.07e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MYC—melanoma	3.55e-06	1.07e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PTEN—melanoma	3.55e-06	1.07e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MYC—melanoma	3.54e-06	1.07e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—MAPK1—melanoma	3.53e-06	1.06e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—NFKB1—melanoma	3.53e-06	1.06e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—EGFR—melanoma	3.53e-06	1.06e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CTNNB1—melanoma	3.52e-06	1.06e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CTNNB1—melanoma	3.52e-06	1.06e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—PIK3CA—melanoma	3.49e-06	1.05e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MYC—melanoma	3.49e-06	1.05e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MYC—melanoma	3.48e-06	1.05e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—MAPK1—melanoma	3.47e-06	1.05e-05	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—EGFR—melanoma	3.47e-06	1.05e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—PIK3CA—melanoma	3.47e-06	1.05e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—MAPK1—melanoma	3.47e-06	1.04e-05	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—EGFR—melanoma	3.47e-06	1.04e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—HRAS—melanoma	3.46e-06	1.04e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—HRAS—melanoma	3.46e-06	1.04e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling by GPCR—AKT1—melanoma	3.46e-06	1.04e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—PIK3CA—melanoma	3.46e-06	1.04e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—PIK3CA—melanoma	3.46e-06	1.04e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MMP9—melanoma	3.45e-06	1.04e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MMP9—melanoma	3.45e-06	1.04e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—CDKN1A—melanoma	3.44e-06	1.04e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—CDKN1A—melanoma	3.44e-06	1.04e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PTEN—melanoma	3.43e-06	1.03e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PTEN—melanoma	3.43e-06	1.03e-05	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—IL6—melanoma	3.43e-06	1.03e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—NFKB1—melanoma	3.41e-06	1.03e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—NFKB1—melanoma	3.41e-06	1.03e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—MAPK1—melanoma	3.41e-06	1.03e-05	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—EGFR—melanoma	3.41e-06	1.03e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PIK3CD—melanoma	3.41e-06	1.03e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—MAPK1—melanoma	3.4e-06	1.02e-05	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—EGFR—melanoma	3.4e-06	1.02e-05	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—TP53—melanoma	3.38e-06	1.02e-05	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—ALB—melanoma	3.36e-06	1.01e-05	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—TP53—melanoma	3.36e-06	1.01e-05	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling by GPCR—AKT1—melanoma	3.35e-06	1.01e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling by GPCR—AKT1—melanoma	3.35e-06	1.01e-05	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—KRAS—melanoma	3.33e-06	1e-05	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—IL6—melanoma	3.31e-06	9.98e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—IL6—melanoma	3.31e-06	9.98e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—HRAS—melanoma	3.31e-06	9.95e-06	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—KRAS—melanoma	3.28e-06	9.88e-06	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—KRAS—melanoma	3.27e-06	9.86e-06	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—HRAS—melanoma	3.23e-06	9.72e-06	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—KRAS—melanoma	3.22e-06	9.7e-06	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PTEN—melanoma	3.21e-06	9.68e-06	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—KRAS—melanoma	3.21e-06	9.67e-06	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—HRAS—melanoma	3.21e-06	9.67e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—VEGFA—melanoma	3.2e-06	9.65e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—HRAS—melanoma	3.2e-06	9.63e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—HRAS—melanoma	3.2e-06	9.63e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—STAT3—melanoma	3.17e-06	9.55e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—NRAS—melanoma	3.16e-06	9.53e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—IL6—melanoma	3.16e-06	9.53e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Immune System—AKT1—melanoma	3.16e-06	9.52e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—VEGFA—melanoma	3.1e-06	9.33e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—VEGFA—melanoma	3.1e-06	9.33e-06	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—IL6—melanoma	3.09e-06	9.3e-06	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—IL6—melanoma	3.07e-06	9.26e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—STAT3—melanoma	3.07e-06	9.24e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—STAT3—melanoma	3.07e-06	9.24e-06	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—PIK3CA—melanoma	3.06e-06	9.22e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—NRAS—melanoma	3.06e-06	9.22e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—NRAS—melanoma	3.06e-06	9.22e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—IL6—melanoma	3.06e-06	9.22e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—IL6—melanoma	3.06e-06	9.22e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Immune System—AKT1—melanoma	3.06e-06	9.21e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Immune System—AKT1—melanoma	3.06e-06	9.21e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MAPK3—melanoma	3.03e-06	9.13e-06	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—PIK3CA—melanoma	3.01e-06	9.08e-06	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—PIK3CA—melanoma	3.01e-06	9.06e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—PIK3CA—melanoma	2.99e-06	9.01e-06	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PIK3CB—melanoma	2.97e-06	8.94e-06	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—TP53—melanoma	2.96e-06	8.92e-06	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—PIK3CA—melanoma	2.96e-06	8.91e-06	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—PIK3CA—melanoma	2.95e-06	8.89e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MYC—melanoma	2.95e-06	8.88e-06	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PTGS2—melanoma	2.94e-06	8.86e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MAPK3—melanoma	2.93e-06	8.83e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MAPK3—melanoma	2.93e-06	8.83e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Disease—AKT1—melanoma	2.92e-06	8.79e-06	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—TP53—melanoma	2.92e-06	8.78e-06	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—TP53—melanoma	2.91e-06	8.76e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—PIK3CA—melanoma	2.89e-06	8.72e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—PIK3CA—melanoma	2.89e-06	8.72e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—MAPK1—melanoma	2.88e-06	8.68e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—EGFR—melanoma	2.88e-06	8.68e-06	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—TP53—melanoma	2.86e-06	8.62e-06	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—TP53—melanoma	2.86e-06	8.6e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MYC—melanoma	2.85e-06	8.59e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MYC—melanoma	2.85e-06	8.59e-06	CbGpPWpGaD
Trifluoperazine—HTR1A—Signaling Pathways—AKT1—melanoma	2.85e-06	8.58e-06	CbGpPWpGaD
Trifluoperazine—HTR2C—Signaling Pathways—AKT1—melanoma	2.84e-06	8.54e-06	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—HRAS—melanoma	2.83e-06	8.53e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Disease—AKT1—melanoma	2.82e-06	8.5e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Disease—AKT1—melanoma	2.82e-06	8.5e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—MAPK1—melanoma	2.79e-06	8.4e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—MAPK1—melanoma	2.79e-06	8.4e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—EGFR—melanoma	2.79e-06	8.4e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—EGFR—melanoma	2.79e-06	8.4e-06	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—HRAS—melanoma	2.79e-06	8.4e-06	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—HRAS—melanoma	2.78e-06	8.38e-06	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—HRAS—melanoma	2.74e-06	8.25e-06	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—HRAS—melanoma	2.73e-06	8.22e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—KRAS—melanoma	2.72e-06	8.2e-06	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—IL6—melanoma	2.71e-06	8.17e-06	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—IL6—melanoma	2.67e-06	8.04e-06	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—IL6—melanoma	2.66e-06	8.02e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—KRAS—melanoma	2.63e-06	7.93e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—KRAS—melanoma	2.63e-06	7.93e-06	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—IL6—melanoma	2.62e-06	7.89e-06	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—IL6—melanoma	2.61e-06	7.87e-06	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PTEN—melanoma	2.57e-06	7.73e-06	CbGpPWpGaD
Trifluoperazine—DRD2—Signaling Pathways—AKT1—melanoma	2.5e-06	7.54e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—PIK3CA—melanoma	2.5e-06	7.53e-06	CbGpPWpGaD
Trifluoperazine—HTR2A—Signaling Pathways—AKT1—melanoma	2.46e-06	7.41e-06	CbGpPWpGaD
Trifluoperazine—HRH1—Signaling Pathways—AKT1—melanoma	2.46e-06	7.4e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Metabolism—AKT1—melanoma	2.44e-06	7.36e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—TP53—melanoma	2.42e-06	7.29e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—PIK3CA—melanoma	2.42e-06	7.29e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—PIK3CA—melanoma	2.42e-06	7.29e-06	CbGpPWpGaD
Trifluoperazine—CHRM2—Signaling Pathways—AKT1—melanoma	2.42e-06	7.28e-06	CbGpPWpGaD
Trifluoperazine—ADRA1A—Signaling Pathways—AKT1—melanoma	2.41e-06	7.26e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Metabolism—AKT1—melanoma	2.36e-06	7.12e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Metabolism—AKT1—melanoma	2.36e-06	7.12e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—TP53—melanoma	2.34e-06	7.05e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—TP53—melanoma	2.34e-06	7.05e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—HRAS—melanoma	2.31e-06	6.97e-06	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—PIK3CA—melanoma	2.27e-06	6.83e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—HRAS—melanoma	2.24e-06	6.74e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—HRAS—melanoma	2.24e-06	6.74e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—IL6—melanoma	2.22e-06	6.67e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—IL6—melanoma	2.14e-06	6.45e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—IL6—melanoma	2.14e-06	6.45e-06	CbGpPWpGaD
Trifluoperazine—CALM3—Signaling Pathways—AKT1—melanoma	2.04e-06	6.16e-06	CbGpPWpGaD
Trifluoperazine—CALM1—Signaling Pathways—AKT1—melanoma	1.98e-06	5.95e-06	CbGpPWpGaD
Trifluoperazine—CALM2—Signaling Pathways—AKT1—melanoma	1.98e-06	5.95e-06	CbGpPWpGaD
Trifluoperazine—ABCB1—Metabolism—AKT1—melanoma	1.85e-06	5.58e-06	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—PIK3CA—melanoma	1.81e-06	5.45e-06	CbGpPWpGaD
Trifluoperazine—CYP1A2—Metabolism—AKT1—melanoma	1.48e-06	4.45e-06	CbGpPWpGaD
